The information to be found in this section is intended for the exclusive use of healthcare professionals
A. Menarini Diagnostics, committed to developing glyco-hemoglobin and hemoglobinopathy analyzers for over 30 years, meets the diagnostic needs of your laboratory with reliable products and services that are able to adapt to constantly evolving situations, providing results that translate into the effective treatment of patients.
A constantly changing scenario
Diabetes monitoring and diagnosis
Diabetes is a chronic metabolic disease associated with severe morbidity, increased mortality and healthcare expenditure and is rapidly becoming a global epidemic, also due to population growth, aging, urbanization, and the increasing prevalence of obesity and physical inactivity. The total number of people suffering from diabetesthroughout the world is expected to rise from 387 million in 2014 to 592 million by 2035.
The International Diabetes Federation estimates that as many as 175 million people worldwide, or close to half of all people with diabetes, are unaware of their disease. The earlier a person is diagnosed and management of diabetes begins, the better the chances of preventing harmful and costly complications.
In this context and proportionally to the growing number of patients, HbA1c assumes an increasingly important role as a tool for diagnosing and monitoring diabetes. This is a major challenge for many laboratories, where it is necessary to have reliable technologies in place to respond to higher workloads and increasingly stringent requirements for accuracy, also for hemoglobinopathies.
Hemoglobinopathies and the role of the laboratory
Hemoglobinopathies are disorders that affect the structure, function, or production of hemoglobin. These disorders are mainly inherited and their clinical manifestations can vary greatly in terms of severity, including asymptomatic laboratory abnormalities and severe clinical-hematological situations.
Hemoglobinopathies – including sickle cell anemia and thalassemia – also represent an emerging problem for global health policies, being among the most common genetic diseases. These disorders have a growing impact on public health also due to immigration and population dynamics, which are changing the characteristics of the clinical populations presenting for healthcare services.
For this reason, laboratory diagnostics assumes an increasingly important role, and must address the managementof hemoglobinopathies in terms of staff training, the organization of diagnostic flows at various levels and interaction with clinicians to identify patients in the population undergoing hematological laboratory tests who require more complex analyses.
In this constantly changing scenario, it is therefore essential for laboratories to be equipped with systems capable of effectively meeting these ever more complex analytical and diagnostic needs.
Premier Hb9210 Resolution